{"abstract": "In presenting long-term financial estimates, AstraZeneca said it expected to achieve annual revenue of $45 billion by 2023, suggesting Pfizer\u2019s bid undervalued the company.", "web_url": "https://dealbook.nytimes.com/2014/05/06/astrazeneca-makes-case-against-pfizers-bid/", "snippet": "In presenting long-term financial estimates, AstraZeneca said it expected to achieve annual revenue of $45 billion by 2023, suggesting Pfizer\u2019s bid undervalued the company.", "lead_paragraph": "Updated, 4:39 p.m. | AstraZeneca, the British drug maker, on Tuesday made an impassioned defense for itself as a stand-alone company, just a day after the American pharmaceutical giant Pfizer again pressed its case for a $106 billion takeover offer. ", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/07/business/dbpix-astrazeneca1/dbpix-astrazeneca1-articleLarge.jpg", "height": 440, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/05/07/business/dbpix-astrazeneca1/dbpix-astrazeneca1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 440}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/07/business/dbpix-astrazeneca1/dbpix-astrazeneca1-jumbo.jpg", "height": 751, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/07/business/dbpix-astrazeneca1/dbpix-astrazeneca1-superJumbo.jpg", "height": 1501, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/07/business/dbpix-astrazeneca1/dbpix-astrazeneca1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/05/07/business/dbpix-astrazeneca1/dbpix-astrazeneca1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/07/business/dbpix-astrazeneca1/dbpix-astrazeneca1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "AstraZeneca Makes Its Case Against Pfizer\u2019s Takeover Bid", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 2, "major": "N"}, {"name": "persons", "value": "Johansson, Leif", "rank": 3, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 5, "major": "N"}, {"name": "glocations", "value": "Great Britain", "rank": 6, "major": "N"}], "pub_date": "2014-05-06T12:02:52+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Jenny Anderson, David Gelles and Stephen Castle", "person": [{"firstname": "Jenny", "middlename": null, "lastname": "Anderson", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}, {"firstname": "David", "middlename": null, "lastname": "Gelles", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 2}, {"firstname": "Stephen", "middlename": null, "lastname": "Castle", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 3}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/0c623b11-bdea-5f49-9e0d-774d02f1951e", "word_count": 1192, "uri": "nyt://article/0c623b11-bdea-5f49-9e0d-774d02f1951e"}